Feline Sarcoma Virus (FeSV) is a retrovirus notorious for instigating sarcomas in cats, serving as a pivotal tool in cancer research. FeSV's knack for integrating its genetic material into the host's genome unleashes unchecked cell proliferation, culminating in tumor genesis. Investigation into FeSV has yielded profound insights into oncogenesis, tumor immunology, and therapeutic modalities. It serves as a potent model for unraveling the complexities of cancer biology, encompassing tumor initiation, progression, and metastasis. The exploration of FeSV's intricacies has catalyzed the innovation of groundbreaking cancer treatments and preventive vaccines, benefiting both feline and human cohorts. By deciphering the nuances of FeSV-induced oncogenesis, researchers strive to unveil overarching principles pivotal in combatting cancer across species domains.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China